Scandinavian Real Heart (HEART) Q2 2025 earnings summary

Executive summary

• Showcased in a major European documentary and featured in a peer-reviewed journal, highlighting technological advances and adaptability of the artificial heart system.

• Secured new patents in the US and Japan, strengthening intellectual property protection in key markets.

• Elected a new chairman and added board members to enhance strategic leadership.

• Received significant capital infusions from share issues and grants, supporting ongoing R&D.

Financial highlights

• Operating income for Q2 2025 was SEK 20,592, down from SEK 30,322 in Q2 2024.

• Net loss after financial items for Q2 2025 was SEK -8.7 million, compared to SEK -6.3 million in Q2 2024.

• Cash and cash equivalents at period end were SEK 27.9 million.

• No product sales; all income is from other operating sources.

Outlook and guidance

• Focus remains on completing preclinical studies and preparing for clinical trials.

• Shifted from quarterly to semi-annual reporting to increase operational efficiency.

• Ongoing efforts to secure additional funding for long-term operations.